Executive Summary: The global triple negative breast cancer market was valued at USD 1.06 billion in 2024 and is expected to reach USD 1.63 billion by 2032 During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 5.50%, primarily driven by the rising incidence rates, increasing R&D investments, and growing adoption of targeted therapies. The Triple Negative...